Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for XOMA Royalty Corporation’s 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) provides access to regulatory documents that reference this preferred security and its issuer. XOMA Royalty’s Form 8-K filings identify XOMAP as a class of securities registered under Section 12(b) of the Securities Exchange Act and list it alongside the company’s common stock and Series B preferred depositary shares on The Nasdaq Global Market.
Through this page, readers can review current and historical filings where XOMA Royalty reports material events, such as the completion of acquisitions of Turnstone Biologics and HilleVax, tender offers, and the use of contingent value rights in transaction structures. These documents often describe how XOMA Royalty acquires milestone and royalty rights linked to therapeutic candidates and how those transactions may affect the company’s overall financial position, which is relevant context for holders of the Series A preferred stock.
Key filings may include Form 8-K reports on completed mergers, tender offers, and financial results, as well as disclosures that list all securities registered for trading, including XOMAP. For investors focused on preferred stock, these filings can help clarify the issuer’s corporate actions, portfolio evolution, and capital structure decisions.
Stock Titan enhances this information by pairing raw SEC documents with AI-powered tools that can help explain filing sections in plain language, highlight items related to preferred securities, and surface references to dividends or other matters affecting XOMAP. Users can use this page to follow new Form 8-K submissions, periodic reports, and other SEC documents as they are made available through EDGAR.
XOMA Royalty Corporation is a biotech royalty aggregator, recently reincorporated to Nevada in May 2025. As of June 30, 2025 total assets were $223,456 thousand and total unrestricted and restricted cash and cash equivalents were $78,485 thousand. Management concluded its cash balance is sufficient to fund planned operations, commitments, and contractual obligations for at least one year.
For the three months ended June 30, 2025 total income and revenues were $13,129 thousand and net income was $9,191 thousand, compared with net income of $15,985 thousand in the prior-year quarter. For the six months ended June 30, 2025 total income and revenues were $29,041 thousand and net income was $11,558 thousand. Income from operations was $4,603 thousand for the quarter versus an operating loss of $10,079 thousand in the comparable prior quarter. Stockholders' equity increased to $72,435 thousand from $61,902 thousand at December 31, 2024.
The company paid $20,614 thousand for a BioInvent contract-based intangible asset during the period, recorded long-term debt of $102,201 thousand and convertible preferred stock of $20,019 thousand. The Company reclassified its Series X Convertible Preferred Stock as mezzanine (temporary) equity and restated comparative balances, which management judged immaterial.